Leerink analyst Jason Gerberry believes no tangible outcomes are likely to result from the House Committee Hearing on Mylan's EpiPen. Nonetheless, the analyst highlights that CEO Heather Bresch stated at the hearing that the company has invested in a new formulation of EpiPen, with a 24-month shelf life versus the current 12-month. Gerberry believes this is a relatively modest benefit and says he is skeptical the line extension will be able to preserve meaningful share if/when an AB-rated generic gets approved. The analyst reiterates an Outperform rating on the shares.